A carregar...
4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease
BACKGROUND: Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha). PURPOSE: To assess prescr...
Na minha lista:
| Publicado no: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Group
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535236/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.248 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|